Close

UPDATE: Rosetta Genomics (ROSG) Ramps On New Buy Rating; Analyst Sees 238% Upside

Go back to UPDATE: Rosetta Genomics (ROSG) Ramps On New Buy Rating; Analyst Sees 238% Upside